DBVTF DBV Technologies S.A.

Nasdaq Biological Products, (No Diagnostic Substances) I0 CIK: 0001613780
AI RATING
STRONG_SELL
95% Confidence

Investment Thesis

DBV Technologies is experiencing severe financial distress with collapsing revenue (-73.6% YoY), massive operating losses (-$102M), and negative free cash flow (-$86.2M), indicating the company is burning through its cash reserves at an unsustainable rate. Despite maintaining adequate liquidity currently, the company's fundamental business model is broken with a -2046% net margin, and at current burn rates, cash runway appears critically limited.

Strengths

  • + Strong current liquidity position with $69.8M cash and 1.80x current ratio
  • + Minimal debt burden with only $510K long-term debt and 0.01x debt/equity ratio
  • + Modest insider activity suggests some management engagement despite challenges

Risks

  • ! Revenue collapse of 73.6% YoY indicates failed commercialization or market rejection of core products
  • ! Operating cash burn of $86.2M annually unsustainable given current cash reserves of $69.8M
  • ! Massive operating losses with -2043.8% operating margin suggest fundamental business model failure
  • ! Negative ROE of -193.2% and ROA of -92.4% indicate severe capital inefficiency
  • ! Complete dependence on cash reserves for survival with no path to profitability visible

Key Metrics to Watch

Financial Metrics

Revenue
5.0M
Net Income
-102.1M
EPS (Diluted)
$-0.82
Free Cash Flow
-86.2M
Total Assets
110.5M
Cash
69.8M

Profitability Ratios

Gross Margin N/A
Operating Margin -2,043.8%
Net Margin -2,046.0%
ROE -193.2%
ROA -92.4%
FCF Margin -1,726.4%

Balance Sheet & Liquidity

Current Ratio
1.80x
Quick Ratio
1.80x
Debt/Equity
0.01x
Debt/Assets
52.2%
Interest Coverage
N/A
Long-term Debt
510.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-03-23T10:24:10.764473 | Data as of: 2025-09-30 | Powered by Claude AI